Joleen Liburd, DO
Family Medicine · Pikesville, MDNPI 1134423866
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 77 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $442, 2.8 times the $159 reported in 2019.
Across 77 payments — averaging $22.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$358
- Novo Nordisk$269
- AbbVie$258
- Amgen$212
- GSK$203
- AstraZeneca$177
- plus $246 from 9 others
Across 45 payments — averaging $3476.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sumitomo Pharma America, Inc.$95K
- Incyte Corporation$27K
- Chiesi USA, Inc.$18K
- GSK$16K
What the payments were for
- Food & beverage$1,723100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 18 | $358 |
| Novo Nordisk | 12 | $269 |
| AbbVie | 13 | $258 |
| Amgen(2 entities) | 7 | $212 |
| GSK | 11 | $203 |
| AstraZeneca | 3 | $177 |
| Pfizer | 3 | $61 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $40 |
| Abbott | 2 | $33 |
| Phadia US Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Exact Sciences | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEZSPIRE$131
How this compares
$1,723 in reported general payments places this provider in the 75th percentile of 1,193 family medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 51 | $64,521 |
| OzempicSemaglutide | 21 | $22,039 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $21,368 |
| EliquisApixaban | 14 | $19,636 |
| TrulicityDulaglutide | 11 | $10,764 |
| Atorvastatin Calcium | 171 | $2,522 |
| Metoprolol Succinate | 94 | $2,328 |
| Pravastatin Sodium | 49 | $1,791 |
| Amlodipine Besylate | 148 | $1,711 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 43 | $1,328 |
| Pantoprazole Sodium | 67 | $1,266 |
| Rosuvastatin Calcium | 37 | $1,144 |
| Losartan Potassium | 63 | $1,139 |
| Metformin Hcl | 73 | $1,092 |
| ClopidogrelClopidogrel Bisulfate | 31 | $999 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $12 | $64,52151 claims |
| Novo NordiskOzempic | $269 | $22,03921 claims |
| GSKTrelegy Ellipta | $203 | $21,36812 claims |
| PfizerEliquis | $61 | $19,63614 claims |
| Lilly USA, LLCTrulicity | $358 | $10,76411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,193 family medicine providers in Maryland.
Other family medicine in Pikesville
- Karen DonaldsonBaltimore$899K
- Louis JacquesBaltimore$522K
- Michael ObiefuneBaltimore$291K
- Thomas LawrenceBerlin$254K
- Casey ScottCambridge$88K
- Daljeet SalujaBaltimore$63K
- Sanjay SaxenaHagerstown$60K
- Cynthia KleppingerSilver Spring$51K
- Tramaine DavisBowie$43K
- Alkesh PatelColumbia$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.